RE: Re:PE1296, LDN Now Petition to the ish Parliament Public Petition

[Guest guest]

Hi Dave,

Good points, that is why only the Government can afford to do a

large scale trial – should they wish to go down this route ie £100m

(US$150m).  Also, this is rapidly becoming a human rights issue so please

folks, do sign the European Parliament petition which is focussing on this

issue if you haven’t already.  Dr Steele MBE is fully supporting

the LDNNow campaign – here’s the link to the petition http://www.ipetitions.com/petition/ldnnow/

Today we are supposedly getting a more considerate and proper

response from our NIHR in the UK re our application to fund further research

into LDN – one mistake they made in their response was that they said ‘we

are quite happy with the medications already offered to people suffering from

these diseases’.  Really?  What about those with SPMS or PPMS where there

are no options/medications available?  And also for Crohns - mesalazine which

causes kidney failure.  Our Government are happy with that?  I think their

initial response left a big loophole for us to keep banging their door down –

and we at LDNNow will!  Just looking forward to our response from our Prime

Minister!

Thanks for the helpful post.  Again folks, please do sign and

support our petition to the European Parliament.

Jayne Crocker

www.LDNNow.com

Important! Please sign our LDN petition to the

European Parliament by clicking here

tel: +44 (0) 7877 492 669

Dr Steele MBE, talking about LDN

LDNNow, a patient and friend led organisation (so not a charity)

with no funding and no affiliation to any company or organisation, but rather a

group of concerned individuals focussed on improving the health of those who

suffer from the many diseases and conditions that LDN treats.

From: low dose naltrexone

[mailto:low dose naltrexone ] On Behalf Of

Sent: 05 March 2010 07:54

low dose naltrexone

Subject: [low dose naltrexone] Re:PE1296, LDN Now Petition to the ish

Parliament Public Petition

According

to the Health Committee report human trials have limited value in determining

the effectiveness of drugs. This is a quote from chapter 4 of that report (The

Influence of the Pharmaceutical Industry) 5 Apr 2005. Also as far as MS is

concerned LDN is dose critical and therefore another problem when designing a

clinical trial.

56. Human

trials tend to have limited predictive value due to problems of extrapolation

to routine clinical practice. Typically, only a small sample of the prospective

population to be exposed to the drug can be studied in clinical trials.

Furthermore, those patients who will probably be exposed to the drug if it is

marketed may be excluded from clinical trials because they have multiple

pathologies or take a number of different medicines. These co-morbidities and

the presence of other drugs in the body might affect the drug being

investigated and not allow accurate comparison with a placebo or comparator

drug.

May be

something you can draw to the attention of the petition committee?